AIM: Gallic acid and its ester derivatives have shown antifungal activity in vitro. This study was performed to investigate their activity against Candida albicans and their toxicity in the animal models Caenorhabditis elegans and zebrafish embryos. RESULTS: The compounds protected worms from C. albicans infection. The dodecyl gallate was the most effective. In zebrafish embryo, gallic acid and dodecyl gallate were the least toxic. CONCLUSION: Gallic acid and its ester derivatives have potential for in vivo use against C. albicans infection. The antifungal effects and toxicity of gallate esters in these alternative animal models were dependent on carbon chain length.
AIM: Gallic acid and its ester derivatives have shown antifungal activity in vitro. This study was performed to investigate their activity against Candida albicans and their toxicity in the animal models Caenorhabditis elegans and zebrafish embryos. RESULTS: The compounds protected worms from C. albicansinfection. The dodecyl gallate was the most effective. In zebrafish embryo, gallic acid and dodecyl gallate were the least toxic. CONCLUSION:Gallic acid and its ester derivatives have potential for in vivo use against C. albicansinfection. The antifungal effects and toxicity of gallate esters in these alternative animal models were dependent on carbon chain length.
Entities:
Keywords:
alternative animal models; antifungal development; gallates; gallic acid; infection
Authors: Claudriana Locatelli; Rober Rosso; Maria C Santos-Silva; Camila A de Souza; Marley A Licínio; Paulo Leal; Maria L Bazzo; Rosendo A Yunes; Tânia B Creczynski-Pasa Journal: Bioorg Med Chem Date: 2008-01-31 Impact factor: 3.641
Authors: Ewa Król; Anabela de Sousa Borges; Isabel da Silva; Carlos R Polaquini; Luis O Regasini; Henrique Ferreira; Dirk-Jan Scheffers Journal: Front Microbiol Date: 2015-04-29 Impact factor: 5.640
Authors: Wafaa M Hikal; Hussein A H Said-Al Ahl; Amra Bratovcic; Kirill G Tkachenko; Javad Sharifi-Rad; Miroslava Kačániová; Mohammed Elhourri; Maria Atanassova Journal: Evid Based Complement Alternat Med Date: 2022-05-13 Impact factor: 2.650
Authors: Patrick Van Dijck; Jelmer Sjollema; Bruno P Cammue; Katrien Lagrou; Judith Berman; Christophe d'Enfert; David R Andes; Maiken C Arendrup; Axel A Brakhage; Richard Calderone; Emilia Cantón; Tom Coenye; Paul Cos; Leah E Cowen; Mira Edgerton; Ana Espinel-Ingroff; Scott G Filler; Mahmoud Ghannoum; Neil A R Gow; Hubertus Haas; Mary Ann Jabra-Rizk; Elizabeth M Johnson; Shawn R Lockhart; Jose L Lopez-Ribot; Johan Maertens; Carol A Munro; Jeniel E Nett; Clarissa J Nobile; Michael A Pfaller; Gordon Ramage; Dominique Sanglard; Maurizio Sanguinetti; Isabel Spriet; Paul E Verweij; Adilia Warris; Joost Wauters; Michael R Yeaman; Sebastian A J Zaat; Karin Thevissen Journal: Microb Cell Date: 2018-06-14